Literature DB >> 33563890

First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018.

Mirian Brink1, Otto Visser2, Sonja Zweegman3, Pieter Sonneveld4, Annemiek Broyl4, Niels W C J van de Donk3, Avinash G Dinmohamed5,3,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33563890      PMCID： PMC7873037          DOI： 10.1038/s41408-021-00415-5

Source DB:  PubMed          Journal:  Blood Cancer J        ISSN： 2044-5385            Impact factor:   11.037


× No keyword cloud information.
  14 in total

1.  Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.

Authors:  P Musto; V Simeon; M C Martorelli; M T Petrucci; N Cascavilla; F Di Raimondo; T Caravita; F Morabito; M Offidani; A Olivieri; G Benevolo; R Mina; R Guariglia; G D'Arena; G Mansueto; N Filardi; F Nobile; A Levi; A Falcone; M Cavalli; G Pietrantuono; O Villani; S Bringhen; P Omedè; R Lerose; L Agnelli; K Todoerti; A Neri; M Boccadoro; A Palumbo
Journal:  Leukemia       Date:  2013-08-20       Impact factor: 11.528

2.  Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience.

Authors:  Daniel Lebovic; Ling Zhang; Melissa Alsina; Taiga Nishihori; Kenneth H Shain; Daniel Sullivan; Jose L Ochoa-Bayona; Mohamed A Kharfan-Dabaja; Rachid Baz
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-08-02

3.  Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.

Authors:  Eirini Katodritou; Evangelos Terpos; Charikleia Kelaidi; Maria Kotsopoulou; Sossana Delimpasi; Marie-Christine Kyrtsonis; Argiris Symeonidis; Nikos Giannakoulas; Aikaterini Stefanoudaki; Dimitrios Christoulas; Christina Chatziaggelidou; Vassiliki Gastari; Nikos Spyridis; Evgenia Verrou; Pavlina Konstantinidou; Kostas Zervas; Meletios A Dimopoulos
Journal:  Am J Hematol       Date:  2013-11-21       Impact factor: 10.047

Review 4.  How I treat plasma cell leukemia.

Authors:  Niels W C J van de Donk; Henk M Lokhorst; Kenneth C Anderson; Paul G Richardson
Journal:  Blood       Date:  2012-07-26       Impact factor: 22.113

5.  Primary plasma cell leukemia and autologous stem cell transplantation.

Authors:  Mary B Drake; Simona Iacobelli; Anja van Biezen; Curly Morris; Jane F Apperley; Dietger Niederwieser; Bo Björkstrand; Gösta Gahrton
Journal:  Haematologica       Date:  2010-05       Impact factor: 9.941

6.  Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.

Authors:  Binod Dhakal; Sagar Patel; Saulius Girnius; Lohith Bachegowda; Raphael Fraser; Omar Davila; Abraham S Kanate; Amer Assal; Amr Hanbali; Asad Bashey; Attaphol Pawarode; César O Freytes; Cindy Lee; David Vesole; Robert Frank Cornell; Gerhard C Hildebrandt; Hemant S Murthy; Hillard M Lazarus; Jan Cerny; Jean A Yared; Jeffrey Schriber; Jesus Berdeja; Keith Stockerl-Goldstein; Kenneth Meehan; Leona Holmberg; Melhem Solh; Miguel Angel Diaz; Mohamed A Kharfan-Dabaja; Nosha Farhadfar; Qaiser Bashir; Reinhold Munker; Richard F Olsson; Robert P Gale; Ruthlee-Lu Bayer; Sachiko Seo; Saurabh Chhabra; Shahrukh Hashmi; Sherif M Badawy; Taiga Nishihori; Wilson Gonsalves; Yago Nieto; Yvonne Efebera; Shaji Kumar; Nina Shah; Muzaffar Qazilbash; Parameswaran Hari; Anita D'Souza
Journal:  Leukemia       Date:  2020-04-20       Impact factor: 11.528

Review 7.  European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias.

Authors:  Maria Gavriatopoulou; Pellegrino Musto; Jo Caers; Giampaolo Merlini; Efstathios Kastritis; Niels van de Donk; Francesca Gay; Ute Hegenbart; Roman Hajek; Sonja Zweegman; Benedetto Bruno; Christian Straka; Meletios A Dimopoulos; Hermann Einsele; Mario Boccadoro; Pieter Sonneveld; Monika Engelhardt; Evangelos Terpos
Journal:  Leukemia       Date:  2018-07-23       Impact factor: 11.528

8.  Completeness of cancer registration in Limburg, The Netherlands.

Authors:  L J Schouten; P Höppener; P A van den Brandt; J A Knottnerus; J J Jager
Journal:  Int J Epidemiol       Date:  1993-06       Impact factor: 7.196

9.  Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.

Authors:  Bruno Royer; Stéphane Minvielle; Momar Diouf; Murielle Roussel; Lionel Karlin; Cyrille Hulin; Bertrand Arnulf; Margaret Macro; Sylvie Cailleres; Annie Brion; Sabine Brechignac; Karim Belhadj; Marie Lorraine Chretien; Marc Wetterwald; Carine Chaleteix; Mourad Tiab; Xavier Leleu; Laurent Frenzel; Laurent Garderet; Sylvain Choquet; Jean Gabriel Fuzibet; Charles Dauriac; Luc-Matthieu Forneker; Lotfi Benboubker; Thierry Facon; Philippe Moreau; Hervé Avet-Loiseau; Jean Pierre Marolleau
Journal:  J Clin Oncol       Date:  2016-04-25       Impact factor: 44.544

10.  Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.

Authors:  Eirini Katodritou; Evangelos Terpos; Sossana Delimpasi; Maria Kotsopoulou; Eurydiki Michalis; Chrysanthi Vadikolia; Marie-Christine Kyrtsonis; Argiris Symeonidis; Nikolaos Giannakoulas; Chrissa Vadikolia; Michalis Michael; Christina Kalpadakis; Theodora Gougopoulou; Chrystalla Prokopiou; Georgia Kaiafa; Dimitrios Christoulas; Maria Gavriatopoulou; Evlampia Giannopoulou; Vasiliki Labropoulou; Evgenia Verrou; Efstathios Kastritis; Pavlina Konstantinidou; Achilles Anagnostopoulos; Meletios A Dimopoulos
Journal:  Blood Cancer J       Date:  2018-03-09       Impact factor: 11.037
View more
  1 in total

1.  Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy.

Authors:  Jingjing Deng; Yuehui Lin; Defeng Zhao; Chunrong Tong; Alex H Chang; Wenming Chen; Wen Gao
Journal:  Front Oncol       Date:  2022-09-21       Impact factor: 5.738
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.